Introduction: Globally head and neck cancer is 7th most common cancer with more than 66,000 new cases and about 50% deaths annually. In India, head and neck cancer incidence is higher as compared to western world due to risk factors like oral tobacco, betel nut chewing, Pan masala, poor oral hygiene, and smoking habits.

Material and Method: We included 120 Patients. All patients were treated with radical intent. All the patients were histologically proven advanced head and neck carcinoma from stage II, III & IV in 8-month duration from – Sept 22 to April 23, patients were divided into two arms.

Conclusion: Weekly paclitaxel with the dose of 75 mg/nm2 with radiotherapy can be considered as a promising and feasible alternative for the treatment of locally advanced Head and Neck Carcinoma.

Haematological toxicities mucositis and skin reaction was higher but manageable. xerostomia and the loss of taste was reported more in cisplatin arm.

Keywords: Head and Neck Carcinoma; Oral Cancer; Chemoradiotherapy

References

1. Sung H., et al. “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries”. CA Cancer Journal of Clinics 71 (2021): 209-249.
2. Johnson D E., et al. “Head and neck squamous cell carcinoma”. Nature Reviews Disease Primers 6 (2020): 92.
3. Vokes EE. “Combined modality therapy of head and neck cancer”. Oncology (Willston Park) 11 (1997): 27-30.
4. Vigneswaran N and Williams MD. “Epidemiologic trends in head and neck cancer and aids in diagnosis”. Oral and Maxillofacial Surgery Clinics of North America 26 (2014): 123-141.
5. Chi AC., et al. “Oral cavity and oropharyngeal squamous cell carcinoma--an update”. CA Cancer Journal of Clinics 65 (2015): 401-421.
6. Agrawal AK., et al. “Treatment delay in Oral and oropharyngeal cancer in our population: the role of socio-economic factors and health seeking behaviour”. Indian Journal of otolaryngology, Head and neck Surgery 63 (2011): 145-150.
7. Kumar S., et al. “Delay in presentation of oral cancer, a multi factor analytical study”. The National Medical Journal of India 14 (2001): 15-17.
8. Bourhis J and Eschwege F. “Radiotherapy-chemotherapy combinations in head and neck squamous cell carcinoma cell: overview of randomized trials”. Anticancer Research 16 (1996): 2397-2402.
9. Schiff PB., et al. “Promotion of microtubule assembly in vitro by Taxol”. Nature 277 (1979): 665-667.
10. Shciff PB and Hortwiz SB. “Taxol stabilizes microtobules in mouse fibroblast cells”. Proceedings of the National Academy of Sciences of the United States of America 77 (1980): 1561-1565.
11. Terasima R and Tolmach LJ. “X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells”. Science 140 (1963): 49-42.
12. Milas L., et al. “Role of reoxygenation in induction of enhancement of tumor radio response by paclitaxel”. Cancer Research 55 (1995): 3564-3568.
13. Hamad RH and Eman Elzahaf. “Low Dose Weekly Paclitaxelv versus Low Dose Weekly Cisplatin with Concomitant Radiation in Locally Advacned Head and Neck Cancers”. Journal of Cancer Science and Therapy 3 (2011): 7.
14. Jain RK., et al. “A comparative study of low dose weekly Paclitaxel versus Cisplatin with concurrent radiation in treatment of Locally Advanced Head and neck Carcinoma”. Indian Journal of Cancer 46 (2007): 50-53.
15. Hoffmann W., et al. “Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer-results from a phase I trial”. International Journal of Radiation Oncology - Biology - Physics 38 (1997): 691-696.
16. Steinberg L., et al. “A phase I trial of radiotherapy and simultaneous 24-hour paclitaxel in patients with locally advanced head and neck squamous cell carcinoma”. Seminar on Oncology 24 (1997): S19-51-56.
17. Madhavan R., et al. “A comparative study of radical radiotherapy with weekly paclitaxel versus radical radiotherapy with weekly cisplatin in the management of locally advanced squamous cell carcinomas of head and neck”. International Journal of Research in Medical Sciences (2017).
18. Lovey J., et al. “Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer”. Radiotherapy Oncology 68 (2003): 171-174.
19. Tishler RB., et al. “An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies”. International Journal of Radiation Oncology - Biology - Physics 43 (1999): 1001-1008.
20. Sunwoo JB., et al. “Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer”. Journal of Oncology 19 (2001): 800-811.

Citation

Citation: Seema Devi., et al. “Comparative Analysis of Weekly Cisplatin Versus Weekly Paclitaxel with Radiotherapy in Locally Advanced Head and Neck Cancer”.Acta Scientific Cancer Biology 8.3 (2024): 17-21.

Copyright

Copyright: © 2024 Seema Devi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.